Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24576857 | 0.95 | CYP2D6 (0.39) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL10254913 | 0.95 | CYP2D6 (0.42) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL12911789 | 0.92 | CYP2D6 (0.41) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL10111445 | 0.92 | CYP2D6 (0.46) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL14768435 | 0.90 | CYP2D6 (0.39) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL19194777 | 0.90 | CYP2D6 (0.39) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL7770721 | 0.89 | CYP2D6 (0.45) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL12911786 | 0.88 | CYP2D6 (0.38) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL19194778 | 0.88 | CYP2D6 (0.38) | CYP2D6HRH3CHRNA7ALDH1A1KDM4E | |
| SCHEMBL24941850 | 0.87 | CYP2D6 (0.35) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-07-18 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | PIM1, PIM2, PIM3 | CYP2D6 1321/4885HRH3 2576/4885CHRNA7 4789/4885 |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | SIGMAR1, TMEM97, OPRD1 | CYP2D6 193/4885HRH3 192/4885CHRNA7 129/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | CYP2D6 4337/4885HRH3 454/4885CHRNA7 3469/4885 |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | CYP2D6 71/4885HRH3 973/4885CHRNA7 4828/4885 |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | CYP2D6 133/4885HRH3 866/4885CHRNA7 3862/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | CYP2D6 2058/4885HRH3 3426/4885CHRNA7 4878/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | CYP2D6 4118/4885HRH3 2812/4885CHRNA7 4552/4885 |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, SLC26A4 | CYP2D6 3373/4885HRH3 2523/4885CHRNA7 966/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | CYP2D6 133/4885HRH3 866/4885CHRNA7 3862/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CYP2D6 3897/4885HRH3 2014/4885CHRNA7 4633/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | CYP2D6 1709/4885HRH3 1364/4885CHRNA7 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.